Highlights Dimerix Limited

Equities

DXB

AU000000DXB7

Market Closed - Australian S.E. Other stock markets 02:10:59 2024-05-14 EDT			5-day change	1st Jan Change
0.34 ^AUD	+4.62%		-2.86%	+65.85%

05-01	Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	MT
04-22	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	04-30	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-25	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	11-27	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	11-07	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	23-07-05	MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	23-07-02	MT
Rights Issue: 1 new share @ 0.08 ASX for 3 existing shares; Rights Issue: 1 new share @ 0.08 AUD for	23-05-07	FA
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8%	23-02-16	MT
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial	23-02-09	MT
Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial	23-02-08	CI
US FDA Confirms Inclusion of Adolescent Children in Dimerix's Trial for Kidney Disease Treatment	23-01-12	MT
Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS	23-01-11	CI
Dimerix Limited Confirms Recruitment of the First 72 Patients to its DMX-200 ACTION3 Phase 3 Trial in Patients with FSGS Kidney Disease Had Been Achieved	22-12-14	CI
Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome	22-12-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dimerix Limited

Equities

DXB

AU000000DXB7

Highlights

Filters